PharmaShots | Incisive News in 3 Shots

Subscribe Now

dMMR

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for dMMR or MSI-H mCRC After Prior Chemotherapy

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for dMMR or MSI-H mCRC After Prior Chemotherapy

June 30, 2021

BMS Receive the CHMP's Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC After Prior Chemotherapy

BMS Receive the CHMP's Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC A...

May 24, 2021

GSK's Jemperli (dostarlimab-gxly) Receives the US FDA's Approval for dMMR Endometrial Cancer

GSK's Jemperli (dostarlimab-gxly) Receives the US FDA's Approval for dMMR Endometrial Cancer

April 23, 2021

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or...

January 27, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us